Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease.
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
received:
30
06
2023
accepted:
23
02
2024
pubmed:
16
4
2024
medline:
16
4
2024
entrez:
15
4
2024
Statut:
ppublish
Résumé
Prasinezumab, a monoclonal antibody that binds aggregated α-synuclein, is being investigated as a potential disease-modifying therapy in early-stage Parkinson's disease. Although in the PASADENA phase 2 study, the primary endpoint (Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) sum of Parts I + II + III) was not met, prasinezumab-treated individuals exhibited slower progression of motor signs than placebo-treated participants (MDS-UPDRS Part III). We report here an exploratory analysis assessing whether prasinezumab showed greater benefits on motor signs progression in prespecified subgroups with faster motor progression. Prasinezumab's potential effects on disease progression were assessed in four prespecified and six exploratory subpopulations of PASADENA: use of monoamine oxidase B inhibitors at baseline (yes versus no); Hoehn and Yahr stage (2 versus 1); rapid eye movement sleep behavior disorder (yes versus no); data-driven subphenotypes (diffuse malignant versus nondiffuse malignant); age at baseline (≥60 years versus <60 years); sex (male versus female); disease duration (>12 months versus <12 months); age at diagnosis (≥60 years versus <60 years); motor subphenotypes (akinetic-rigid versus tremor-dominant); and motor subphenotypes (postural instability gait dysfunction versus tremor-dominant). In these subpopulations, the effect of prasinezumab on slowing motor signs progression (MDS-UPDRS Part III) was greater in the rapidly progressing subpopulations (for example, participants who were diffuse malignant or taking monoamine oxidase B inhibitors at baseline). This exploratory analysis suggests that, in a trial of 1-year duration, prasinezumab might reduce motor progression to a greater extent in individuals with more rapidly progressing Parkinson's disease. However, because this was a post hoc analysis, additional randomized clinical trials are needed to validate these findings.
Identifiants
pubmed: 38622249
doi: 10.1038/s41591-024-02886-y
pii: 10.1038/s41591-024-02886-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1096-1103Informations de copyright
© 2024. The Author(s).
Références
Stefanis, L. α-Synuclein in Parkinson’s disease. Cold Spring Harb. Perspect. Med. 2, a009399 (2012).
doi: 10.1101/cshperspect.a009399
pubmed: 22355802
pmcid: 3281589
Schenk, D. B. et al. First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers. Mov. Disord. 32, 211–218 (2017).
doi: 10.1002/mds.26878
pubmed: 27886407
Jankovic, J. et al. Safety and tolerability of multiple ascending doses of PRX002/RG7935, an anti-α-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial. JAMA Neurol. 75, 1206–1214 (2018).
doi: 10.1001/jamaneurol.2018.1487
pubmed: 29913017
pmcid: 6233845
Pagano, G. et al. Trial of prasinezumab in early-stage Parkinson’s disease. N. Engl. J. Med. 387, 421–432 (2022).
doi: 10.1056/NEJMoa2202867
pubmed: 35921451
Goetz, C. G. et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23, 2129–2170 (2008).
doi: 10.1002/mds.22340
pubmed: 19025984
Lang, A. E. et al. Trial of cinpanemab in early Parkinson’s disease. N. Engl. J. Med. 387, 408–420 (2022).
doi: 10.1056/NEJMoa2203395
pubmed: 35921450
Simuni, T. et al. Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort. J. Neurol. Neurosurg. Psychiatry 89, 78–88 (2018).
doi: 10.1136/jnnp-2017-316213
pubmed: 28986467
Simuni, T. et al. Longitudinal change of clinical and biological measures in early Parkinson’s disease: Parkinson’s progression markers initiative cohort. Mov. Disord. 33, 771–782 (2018).
doi: 10.1002/mds.27361
pubmed: 29572948
pmcid: 6001458
Horváth, K. et al. Minimal clinically important difference on the Motor Examination part of MDS-UPDRS. Parkinsonism Relat. Disord. 21, 1421–1426 (2015).
doi: 10.1016/j.parkreldis.2015.10.006
pubmed: 26578041
Pagano, G. et al. A Phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson’s disease (PASADENA): rationale, design, and baseline data. Front. Neurol. 12, 705407 (2021).
doi: 10.3389/fneur.2021.705407
pubmed: 34659081
pmcid: 8518716
Mollenhauer, B. et al. Baseline predictors for progression 4 years after Parkinson’s disease diagnosis in the De Novo Parkinson Cohort (DeNoPa). Mov. Disord. 34, 67–77 (2019).
doi: 10.1002/mds.27492
pubmed: 30468694
Zolfaghari, S. et al. Self-report versus clinician examination in early Parkinson’s disease. Mov. Disord. 37, 585–597 (2022).
doi: 10.1002/mds.28884
pubmed: 34897818
Joza, S. et al. Progression of clinical markers in prodromal Parkinson’s disease and dementia with Lewy bodies: a multicentre study. Brain 146, 3258–3272 (2023).
doi: 10.1093/brain/awad072
pubmed: 36881989
Calabresi, P. et al. Alpha-synuclein in Parkinson’s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis. 14, 176 (2023).
doi: 10.1038/s41419-023-05672-9
pubmed: 36859484
pmcid: 9977911
Cascella, R. et al. The release of toxic oligomers from α-synuclein fibrils induces dysfunction in neuronal cells. Nat. Commun. 12, 1814 (2021).
doi: 10.1038/s41467-021-21937-3
pubmed: 33753734
pmcid: 7985515